POINT Biopharma Global Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joe A. McCann
- Full Time Employees
- 129
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4850 West 78th Street Indianapolis IN United States of America 46268
- IPO Date
- Jul 8, 2020
- CIK
- 0001811764
- Website
- pointbiopharma.com
- Similar Companies
- Business
- POINT Biopharma Global Inc. POINT Biopharma Global Inc. (PNT) operates as a clinical-stage radiopharmaceutical company focused on the development and commercialization of radioligand therapies for cancer treatment; its core pipeline includes PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy in phase 3 for metastatic castration-resistant prostate cancer (mCRPC); PNT2003, a somatostatin receptor (SSTR)-targeted therapy in phase 3 for gastroenteropancreatic neuroendocrine tumors (GEP-NETs); PNT2001, a preclinical PSMA-targeted alpha-emitter for prostate cancer using actinium-225; PNT2004, a phase 1 fibroblast activation protein (FAP)-targeted therapy for solid tumors; and earlier-stage candidates such as 68Ga-PNT6555 and radio-DARPin programs targeting various neoplasms. The company maintains in-house manufacturing capabilities, secured isotope supplies including lutetium-177 and actinium-225, and partnerships such as licensing agreements with Lantheus Holdings for commercial rights to select programs; it targets precision oncology markets with improved efficacy and safety over traditional chemotherapy. Founded in late 2019 and headquartered in Indianapolis, Indiana, with additional operations in Toronto, Ontario, Canada, POINT conducts global clinical trials and expands access to therapies across North America and international regions. In a major strategic development completed in December 2023, Eli Lilly and Company acquired POINT for approximately $1.4 billion, integrating its radioligand platform as a wholly owned subsidiary to accelerate oncology advancements, including ongoing SPLASH phase 3 trial for PNT2002 and FRONTIER phase 1 for PNT2004, with no significant further acquisitions, partnerships, or pipeline shifts reported through 2025.
Iridium's PNT ASIC: A New Catalyst Beyond Satellite Connectivity?
Iridium Announces Commercial Availability of Iridium PNT ASIC, Bringing Resilient GNSS Protection to Devices Worldwide
Iridium NTN Direct Begins Live Testing with Mlink
Iridium's Next‑Generation Hybrid IoT Module and Development Kit are Now Commercially Available
NextNav Announces Redemption of 5.00% Senior Secured Convertible Notes
NextNav Aims for Safe Drone-dominant Future with GSMA and Industry Partners
NextNav Announces Redemption of Public Warrants
Pheasant Network by PG Labs Raises $2M Seed Round to Accelerate AI-Powered Intent for DeFAI
Australian Defence Science and Technology Group selects Adtran optical cesium clock for PNT research
VIAVI Launches Second Generation RSR Transcoder for Assured PNT in GPS-Denied Environments
Will Adtran's New Oscilloquartz-Assured PNT Solution Drive Top Line?
Adtran demonstrates Oscilloquartz assured PNT solution at Jammertest
Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology
Spirent Announces PNT X – the Next Generation Test Solution for Positioning, Navigation and Timing
Lilly Completes Acquisition of POINT Biopharma
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Lantheus and Point Biopharma shares drop on prostate cancer treatment data
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know